{
  "trial_id": "NCT02911142",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Primary effusion lymphoma (PEL), including extracavitary variant, and KSHV-associated",
      "label": "met"
    },
    {
      "criterion": "large cell lymphoma that is pathologically confirmed by the NCI Laboratory of Pathology",
      "label": "met"
    },
    {
      "criterion": "Measurable or assessable lymphoma.",
      "label": "met"
    },
    {
      "criterion": "Any HIV status",
      "label": "unknown"
    },
    {
      "criterion": "Age 18 years or greater.",
      "label": "met"
    },
    {
      "criterion": "ECOG performance status 0-4.",
      "label": "unknown"
    },
    {
      "criterion": "Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 1 day before starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide.",
      "label": "unknown"
    },
    {
      "criterion": "Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.",
      "label": "unknown"
    },
    {
      "criterion": "Able to take aspirin 81mg orally daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparin.",
      "label": "met"
    },
    {
      "criterion": "Ability of subject to understand and the willingness to sign a written informed consent document.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Use of other systemic anticancer treatments or agents within the past 2 weeks",
      "label": "not_met"
    },
    {
      "criterion": "Phase I or Phase II patients who have prior dose-adjusted EPOCH for treatment for PEL or KSHV-associated large cell lymphoma",
      "label": "unknown"
    },
    {
      "criterion": "Parenchymal brain involvement with lymphoma",
      "label": "not_met"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT02911142",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_test10_top50"
  }
}